Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hiprex versus nitrofurantoin for prevention of recurrent urinary tract infection
ACTRN12617000585325Phase 4Withdrawn
- Sponsor
- Mercy Hospital for Women
- Start
- Jul 2017
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of methenamine hippurate and nitrofurantoin in urinary tract infection (UTI) (2 arms), sponsored by Mercy Hospital for Women. Primary endpoint: Recurrence of urinary tract infection during trial. Planned start Jul 2017; status: withdrawn.
02
Drugs
methenamine hippuratenitrofurantoin
03
Conditions
urinary tract infection (UTI)
Beyond the preview
Go deeper on ACTRN12617000585325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000585325.